Rituximab for autoimmune retinopathy: Results of a Phase I/II clinical trial

PURPOSE: This prospective study evaluates whether rituximab is a safe and potentially effective treatment for nonparaneoplastic autoimmune retinopathy (npAIR). MATERIALS AND METHODS: Five npAIR patients were enrolled in a Phase I/II, prospective, nonrandomized, open-label, single-center study. All p...

全面介绍

书目详细资料

发表在:	Taiwan Journal of Ophthalmology
Main Authors:	Karen R Armbrust, Austin R Fox, Brett G Jeffrey, Patti Sherry, H Nida Sen
格式:	文件
语言:	英语
出版:	Wolters Kluwer Medknow Publications 2021-01-01
主题:	autoimmunity electroretinography retinal degeneration rituximab visual fields
在线阅读:	http://www.e-tjo.org/article.asp?issn=2211-5056;year=2021;volume=11;issue=1;spage=64;epage=70;aulast=Armbrust